C4x Discovery Signs Exclusive Global Licence Worth Up To $402 Million With Astrazeneca

Published on November 28, 2022 08:42 AM CET

C4x Discovery Signs Exclusive Global Licence Worth Up To $402 Million With Astrazeneca — Image source: ©2022 Kalkine Media®

Nov 28 (Reuters) - AstraZeneca PLC:

* SIGNS EXCLUSIVE GLOBAL LICENCE WORTH UP TO $402 MILLION WITH ASTRAZENECA FOR DEVELOPMENT & COMMERCIALISATION OF NRF2 ACTIVATOR PROGRAMME

* C4XD WILL RECEIVE PRE-CLINICAL MILESTONE PAYMENTS WORTH UP TO $16 MILLION AHEAD OF FIRST CLINICAL TRIAL

* IN ADDITION, C4XD IS ELIGIBLE TO RECEIVE A FURTHER POTENTIAL $385.8 MILLION Source text for Eikon: Further company coverage:

Reuters

Reuters -
91946 Posts
...

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.